mProX™ Human CD200R1 Stable Cell Line

Product Information

Target Family

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;PC9;H358

Target Classification

CD Cell Lines

Target Research Area

Cancer Research

Related Diseases

Human Herpesvirus 8; Polycystic Lipomembranous Osteodysplasia With Sclerosing Leukoencephalopathy 1

Gene ID

Human:131450

UniProt ID

Human:Q8TD46

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD200R1 has various applications in different fields. In the context of osteosarcoma (OS), CD200R1 is implicated in influencing the prognostic and immune microenvironment of the disease. It is part of a risk prognostic model for OS and is associated with high-risk and low-risk FRLncs (ferroptosis-related long non-coding RNAs) that can serve as prognostic markers. CD200R1 is also linked to down-regulation of immune cell types and functions in OS. In ovarian cancer (OC), CD200R1 is one of the immune-related biomarkers that are sensitive to platinum-based chemotherapy. It is associated with the prognosis of OC patients and is differentially expressed between high-risk and low-risk groups. CD200R1 is also involved in the regulation of immune checkpoint inhibitors and drug resistance in OC. In the field of depression, CD200R1 plays a role in improving depressive-like behaviors in mice. It enhances hippocampal neurogenesis by alleviating microglia hyperactivation. CD200R1 is expressed in the dentate gyrus and its activation contributes to the antidepressant effect of neurogenesis. In the context of pulmonary fibrosis, CD200R1 is targeted by SHP-1 agonists to reduce inflammation and alleviate fibrosis. Activation of CD200R1 suppresses CSF1R signaling in macrophages, leading to a reduction in pathogenic macrophages and inhibition of fibroblast-to-myofibroblast transition. Finally, in the field of cancer immunotherapy, CD200R1 is targeted by a genetically informed antibody (23ME-00610) to enhance antitumor T cell function. This antibody blocks the CD200:CD200R1 immune checkpoint, leading to immune activation and inhibition of tumor growth. Overall, CD200R1 has diverse applications in cancer research, neurobiology, and immunology.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CD200R1 Stable Cell Line (S01YF-1023-PY220). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Johnson (Verified Customer)

How does CD200R1 signaling influence psoriasis? May 14 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

Reduced CD200:CD200R1 signaling in psoriasis enhances neutrophil recruitment to the skin, indicating its role in immune regulation. May 14 2021

chat Alex Miller (Verified Customer)

Can CD200R1 contribute to functional recovery after a sciatic nerve injury? Apr 03 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

CD200R1 plays a role in mounting a successful acute inflammatory reaction after injury, contributing to effective functional recovery. Apr 03 2021

Published Data

Fig.1 In tumor cells, CD200R1 is linked to cell proliferation activity.

In the left part, the protein levels, representative of CD200R1 knockdown with siRNA in PC9 and H358 cells, were displayed in Western blots, with analysis conducted by CCK-8 assays for the assessment of cell proliferation in PC9 and H358 cells. Scramble RNA-transfected cells served as the negative control (NC), and the data were presented as the mean ± SD, with N = 5 samples. Significance levels were denoted as *P <.05 and **P <.001 vs. NC, as determined by one-way ANOVA.

Ref: Yoshimura, Katsuhiro, et al. "CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer." Oncoimmunology 9.1 (2020): 1746554.

Pubmed: 32395395

DOI: 10.1080/2162402X.2020.1746554

Research Highlights

Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
This study aims to examine the role of ferroptosis-related long non-coding RNAs (FRLncs) in the prognosis and immune microenvironment of osteosarcoma (OS). By establishing a basic framework, this research can provide valuable insight for clinical decision making in OS management. Through investigation and analysis, the authors seek to identify the potential impact of FRLncs on OS and offer guidance for improving treatment strategies. The findings from this study could have important implications for enhancing patient outcomes in OS.
Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
Pubmed: 37858131 DOI: 10.1186/s13018-023-04286-3

Liu, Jiao. et al. "Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer." Translational oncology, 2023.
This study aimed to identify biomarkers that are sensitive to platinum-based chemotherapeutic agents and can potentially be used in immunotherapy for ovarian cancer (OC). Through this research, the authors hope to shed light on the mechanisms of action of these biomarkers and their potential significance in the treatment of this deadly gynecological malignancy. The results of this study may provide valuable insights for future treatment strategies for OC.
Liu, Jiao. et al. "Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer." Translational oncology, 2023.
Pubmed: 37619523 DOI: 10.1016/j.tranon.2023.101762